Celltrion, a Korean pharmaceutical company that is developing as a treatment for Corona 19, has proven that the efficacy of Rekirona is also proven in Europe.
In an interview with TBS’Kim Eo-Jun’s News Factory’ today (4th), Dr. Adrian Strayne Cercher, head of clinical research at the Romanian National Institute of Infectious Diseases, said that the treatment prevents patients who need to be hospitalized, even if they are hospitalized. He said it was found to have no side effects as well as horns that would shorten that period.
Dr. Chercher, who also served as the president of Carol Davila’s medical and pharmacy college in this country, said, “The clinical results of patients with mild and severe cases were very effective, and the rate of oxygen therapy after hospitalization was very reduced.” “There are no patients who have responded or died, so we can quickly use Rekirona as a treatment.”
He added, “The patient recovers quickly,” and said, “The number of days of recovery has been reduced by more than half, and the total amount of virus in the droplet test through the nose has also decreased.”
As an example, “an 85-year-old patient who participated in the phase 2 clinical trial had an underlying disease such as obesity, diabetes, and high blood pressure. After administering the test drug, the symptoms became asymptomatic. As a result of the droplet test, the virus concentration was significantly lowered.” “As a result, in less than 5 days, I completely recovered from my symptoms,” he said.
He said, “It will be more effective to end the corona pandemic if you physically distance yourself, wear a mask, get vaccination well, and use a cure when infected,” he said. I judged it.
He stressed that it should be used immediately in patients because it is so effective and the results are so obvious and obvious that there are no side effects.
<인터뷰 전문>
* When citing content, TBS [김어준의 뉴스공장]Please indicate that this is the content of the interview with the department.
◎ Part 2
[인터뷰 제1공장]
What is Europe’s response to the COVID-19 treatment’Rekironazu’?
“It will increase the therapeutic effect with vaccines”
-Dr. Chercher (Director of Romanian National Institute of Infectious Diseases)
▶ Kim Eo-Joon: Celltrion’s Reekhironaju, which was approved as the first Corona 19 treatment in Korea, is currently undergoing clinical trials worldwide. I would like to meet with Dr. Strainho-Chercher, president of the Romanian National Institute of Infectious Diseases and Carol Davila, president of the University of Medicine and Pharmacy, who has been involved as a clinical researcher in the state of Rekkirona and managed patients. Hello, Doctor.
▷ Chercher: Thank you for inviting me to the interview today. Let me introduce myself again. I am the former President of Carol Davila School of Medicine and Pharmacy and the current Director of Clinical Research at the Romanian National Institute of Infectious Diseases. Currently, he is in charge of clinical research on infectious diseases conducted throughout Romania.
▶ Kim Eo-jun: Yes, thank you. Now, let me start with this question. How did you get involved in this Rekirona state clinical trial?
▷ Chercher: Yes, we are already an institution with a very high reputation for infectious disease research at the Romanian National Institute of Infectious Diseases. In addition, the Romanian Food and Drug Administration has been leading the first, second, and third stages of clinical trials related to coronavirus. So, as Romania has gained a worldwide reputation for these clinical studies, we have this opportunity.
▶ Kim Eo-jun: That’s right. Now, then, what stage has the clinical trial of Rekirona been conducted so far?
▷ Chercher: We just started phase 3, and we have already recruited 100 patients.
▶ Kim Eo-Jun: Well, then, since you are in charge of Romanian infectious diseases, how do you evaluate the effectiveness of Rekkirona, which has been shown through clinical trials so far?
▷ Chercher: Remarkable clinical results came out from the beginning There have been reports that the patient’s recovery was rapid. Recovery days have also been reduced by more than 50%. When looking at the results of a nasopharyngeal swab, or droplet through the nose, the total amount of virus also decreased. Also, the total number of recovery days decreased to less than 6 days, or 5.8 days. The number of recovery days for the control group was 8.8 days. This is a great result. In addition, the tolerability to the test drug was excellent. When looking at the proportion of patients who need hospitalization and oxygen therapy, 7.2% in the group receiving the test drug and 15.8% in the control group consisting of moderate patients. This is a 50% or more reduction in the proportion of patients who need hospitalization and oxygen therapy when taking the test drug. Similarly, when looking at moderate patients aged 50 years or older, the proportion of patients requiring hospitalization and oxygen therapy was 8% in the test drug group and 23.7% in the control group. So, as a result, when it comes to mild and moderate corona patients, the clinical results were very effective, and above all, the rate for hospitalization and oxygen therapy was greatly reduced. In addition, the tolerability of this clinical trial drug was very good.
▶ Kim Eo-jun: What does it mean to be very well tolerated?
▷ Chercher: Good tolerance means that there were no patients who showed adverse reactions or died after receiving this test drug. Therefore, it can be interpreted as meaning that it can be quickly used as a treatment targeting corona patients.
▶ Kim Eo-Joon: Then, to sum up what you have given me now, it prevents the patient who needs to be hospitalized, and the hospitalized patient reduces the number of days to be hospitalized, and prevents it from becoming severely ill, and there were no side effects. Can I understand this?
▷ Chercher: Yes, it is correct.
▶ Kim Eo-jun: That’s right. If so, do you think this Rekirona state will help to resolve the current Corona 19 pandemic to some extent?
▷ Chercher: Yes, I expect it will be one of the ways to end the pandemic. Most of all, by administering this test drug, it would be more effective if you prevent the penetration of the virus and vaccinate it. And if we keep physical distancing and wear masks thoroughly, I think in a year we will be able to tell the pandemic as a history of the past.
▶ Kim Eo-jun: I see. So, there are three ways to end the corona: a mask for prevention, a vaccine to prevent infection, and a treatment in case of infection nonetheless.
▷ Chercher: Yes, that’s right. We recommend that you take these various measures together.
▶ Kim Eo-Joon: You are currently in Phase 3, when will this Phase 3 be over?
▷ Chercher: In the case of Phase III, 112 patients have already registered, so the end of the test for these patients is considered the end point.
▶ Kim Eo-jun: When will that be?
▷ Chercher: I can’t tell you for sure right now. This is because this clinical trial is being conducted in 10 countries around the world, and Romania is only one of them. And because there are clear criteria for patients who can participate in clinical trials, we must follow all criteria step by step. Otherwise, we cannot be sure of the clinical results. Fortunately, there are already 100 patients enrolled in Romania. Thousands of subjects from 10 countries should be recruited within the next three months.
▶ Kim Eo-Joon: From the experience of conducting this clinical trial so far, it is worth recommending the use of Rekirona, do you see it like this?
▷ Chercher: My answer is absolutely “yes”. Above all, clinical drugs are effective and well tolerated. And the results are too obvious. That is why I think it should be used immediately for patients. Among the patients, it is strongly recommended to patients with mild or moderate severity and within 7 days of onset of symptoms.
▶ Kim Eo-jun: I see. You said you saw a clear effect, but is there any specific case we can refer to?
▷ Chercher: Yes, there is a good example. I was an 85-year-old patient who participated in our phase 2 clinical trial. It was a patient with underlying diseases such as obesity, diabetes, and high blood pressure. However, after administering our test drug, it recovered completely. Symptoms have also changed to asymptomatic. As a result of the droplet test, the concentration of the virus was also significantly lowered. So, in the end, it was less than 5 days, and the patient recovered from all symptoms.
▶ Kim Eo-jun: That’s right. Now, at the end of phase 3, we will pick up the final data and connect again.
▷ Chercher: Thank you very much. I’m also looking forward to it.
▶ Kim Eo-jun: Thank you. I’ll do it here today.
▷ Chercher: Thank you.
▶ Kim Eo-Jun: Until now, I was Dr. Strainho-Chercher, who oversees Romanian infectious diseases. And for interpreting?
◐ Interpretation: It was Inna Lee.
Article reporting and press release provided [email protected] / copyrightⓒ tbs. Unauthorized reproduction & redistribution prohibited